Q-omics provides the consensus-scored BNC1 profile across patient tissues and cancer cell-line models. BNC1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BNC1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, BNC1 RNA expression shows 16,406 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, HNSC, and TGCT as cancer lineages where BNC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BNC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BNC1 survival associations across molecular data types. BNC1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BNC1 RNA expression–survival associations across cancer types. High BNC1 expression shows unfavorable associations in UVM, KIRC, OV and UCEC, but favorable associations in THCA and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for BNC1 RNA expression.
This table summarizes BNC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BNC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BNC1 shows lower tumor expression in BRCA and UCEC and higher tumor expression in HNSC, THCA, LUSC and KIRP. The HNSC box plot shows higher BNC1 RNA expression in tumor versus normal tissue (log2 FC = +2.678, t-test p < 0.001).
This table shows molecular features associated with BNC1 in patient tissues and cancer cell lines. In patient samples, BNC1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, BNC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
